A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2018 Planned End Date changed from 30 Nov 2023 to 30 Nov 2022.
- 06 Dec 2018 Planned primary completion date changed from 30 Nov 2023 to 30 Nov 2022.
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.